8.80
price up icon0.46%   0.04
after-market After Hours: 8.80
loading
Sage Therapeutics Inc stock is traded at $8.80, with a volume of 2.93M. It is up +0.46% in the last 24 hours and down -4.86% over the past month. Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$8.76
Open:
$8.79
24h Volume:
2.93M
Relative Volume:
1.59
Market Cap:
$551.06M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-1.0489
EPS:
-8.39
Net Cash Flow:
$-424.74M
1W Performance:
-3.40%
1M Performance:
-4.86%
6M Performance:
+23.94%
1Y Performance:
-15.95%
1-Day Range:
Value
$8.76
$8.82
1-Week Range:
Value
$8.74
$9.105
52-Week Range:
Value
$4.62
$11.44

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name
Name
Sage Therapeutics Inc
Name
Phone
617-299-8380
Name
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Employee
487
Name
Twitter
@SageBiotech
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
SAGE's Discussions on Twitter

Compare SAGE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SAGE
Sage Therapeutics Inc
8.80 548.57M 91.06M -503.14M -424.74M -8.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-11-25 Resumed BofA Securities Underperform
Nov-21-24 Upgrade RBC Capital Mkts Underperform → Sector Perform
Oct-10-24 Resumed Raymond James Mkt Perform
Oct-04-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-30-24 Downgrade TD Cowen Buy → Hold
Jul-25-24 Downgrade JP Morgan Overweight → Neutral
May-29-24 Initiated Citigroup Sell
May-29-24 Initiated Robert W. Baird Neutral
Apr-17-24 Downgrade BofA Securities Neutral → Underperform
Dec-12-23 Initiated Deutsche Bank Hold
Aug-08-23 Downgrade Canaccord Genuity Buy → Hold
Aug-08-23 Downgrade Goldman Buy → Neutral
Aug-08-23 Downgrade Needham Buy → Hold
Aug-07-23 Downgrade BofA Securities Buy → Neutral
Aug-07-23 Downgrade Oppenheimer Outperform → Perform
Aug-07-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-07-23 Downgrade Stifel Buy → Hold
Aug-07-23 Downgrade Wedbush Outperform → Neutral
Jul-27-23 Initiated Scotiabank Sector Outperform
Mar-13-23 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jan-03-23 Downgrade Guggenheim Buy → Neutral
Nov-01-22 Initiated Loop Capital Hold
Mar-31-22 Initiated Berenberg Hold
Nov-02-21 Upgrade Guggenheim Neutral → Buy
Oct-19-21 Resumed Morgan Stanley Equal-Weight
Oct-07-21 Downgrade Jefferies Buy → Hold
Sep-23-21 Initiated Needham Buy
Jun-16-21 Downgrade Citigroup Buy → Neutral
Apr-07-21 Initiated Piper Sandler Overweight
Feb-26-21 Downgrade Mizuho Buy → Neutral
Feb-25-21 Reiterated H.C. Wainwright Neutral
Feb-02-21 Resumed Raymond James Mkt Perform
Jan-22-21 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Jan-04-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-04-20 Upgrade Mizuho Neutral → Buy
Dec-01-20 Downgrade Raymond James Outperform → Mkt Perform
Nov-16-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-06-20 Reiterated H.C. Wainwright Neutral
Sep-11-20 Upgrade Wedbush Neutral → Outperform
Aug-10-20 Upgrade Raymond James Mkt Perform → Outperform
May-08-20 Downgrade Wedbush Outperform → Neutral
Apr-08-20 Downgrade Guggenheim Buy → Neutral
Mar-18-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-06-20 Initiated Citigroup Buy
Feb-28-20 Reiterated H.C. Wainwright Neutral
Feb-06-20 Initiated Mizuho Neutral
Dec-06-19 Reiterated RBC Capital Mkts Outperform
Dec-05-19 Reiterated Guggenheim Buy
Dec-05-19 Downgrade SunTrust Buy → Hold
Oct-30-19 Initiated H.C. Wainwright Neutral
May-23-19 Initiated Wedbush Outperform
Apr-25-19 Initiated Jefferies Buy
Dec-14-18 Initiated Wolfe Research Outperform
Oct-11-18 Initiated Oppenheimer Outperform
View All

Sage Therapeutics Inc Stock (SAGE) Latest News

pulisher
08:15 AM

BML Capital Management LLC Buys New Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat

08:15 AM
pulisher
03:44 AM

Sage Therapeutics (NASDAQ:SAGE) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat

03:44 AM
pulisher
Jul 25, 2025

Sage Therapeutics (SAGE) Expected to Announce Earnings on Wednesday - MarketBeat

Jul 25, 2025
pulisher
Jul 25, 2025

Cwm LLC Acquires 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat

Jul 25, 2025
pulisher
Jul 23, 2025

What drives Sage Therapeutics Inc. stock priceUnbelievable profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Sage Therapeutics Inc. stockFree Investment Community - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Sage Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Sage Therapeutics Inc. a good long term investmentFree Daily Trading Room Entry - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 22, 2025
pulisher
Jul 20, 2025

Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above 50 Day Moving AverageHere's Why - MarketBeat

Jul 20, 2025
pulisher
Jul 18, 2025

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - 富途牛牛

Jul 18, 2025
pulisher
Jul 15, 2025

Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, - openPR.com

Jul 15, 2025
pulisher
Jul 15, 2025

Status Epilepticus Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Marinus Pharmac, Pfizer, UCB Biopharma, Rafa Laboratories, Sage Therapeutics - The Globe and Mail

Jul 15, 2025
pulisher
Jul 14, 2025

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jul 13, 2025
pulisher
Jul 12, 2025

Sage Therapeutics (NASDAQ:SAGE) Downgraded to Hold Rating by Scotiabank - MarketBeat

Jul 12, 2025
pulisher
Jul 11, 2025

SAGE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Sage Therapeutics, Inc. is Fair to Shareholders - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 11, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Connect - ACCESS Newswire

Jul 11, 2025
pulisher
Jul 10, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Analysts - MarketBeat

Jul 10, 2025
pulisher
Jul 10, 2025

Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to “Hold” at Scotiabank - Defense World

Jul 10, 2025
pulisher
Jul 09, 2025

Sage Therapeutics Announces Workforce Reductions Following Recent Acquisition Plans - geneonline.com

Jul 09, 2025
pulisher
Jul 09, 2025

Postpartum Depression Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research - Barchart.com

Jul 09, 2025
pulisher
Jul 08, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out - ACCESS Newswire

Jul 08, 2025
pulisher
Jul 08, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, SAGE, OLO on Behalf of Shareholders - Morningstar

Jul 08, 2025
pulisher
Jul 08, 2025

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

SAGE: Scotiabank Downgrades Sage Therapeutics with Price Target Adjustment | SAGE Stock News - GuruFocus

Jul 08, 2025
pulisher
Jul 08, 2025

Scotiabank Downgrades SAGE Therapeutics to Sector Perform From Sector Outperform, Adjusts Price Target to $9.20 From $12 - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Wealth Enhancement Advisory Services LLC Takes $347,000 Position in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World

Jul 08, 2025
pulisher
Jul 08, 2025

Scotiabank Downgrades Sage Therapeutics (SAGE) - MSN

Jul 08, 2025
pulisher
Jul 07, 2025

Sage Therapeutics (NASDAQ:SAGE) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat

Jul 07, 2025
pulisher
Jul 06, 2025

Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN

Jul 06, 2025
pulisher
Jul 06, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jul 06, 2025
pulisher
Jul 06, 2025

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Rating of “Hold” from Analysts - Defense World

Jul 06, 2025
pulisher
Jul 04, 2025

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 04, 2025
pulisher
Jul 03, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE - Eastern Progress

Jul 03, 2025
pulisher
Jul 01, 2025

Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 01, 2025
pulisher
Jul 01, 2025

What Makes Sage Therapeutics (SAGE) a New Buy Stock - Yahoo Finance

Jul 01, 2025
pulisher
Jun 30, 2025

Sage to lay off most staff amid Supernus buyout - BioPharma Dive

Jun 30, 2025
pulisher
Jun 29, 2025

Levi & Korsinsky Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE - ACCESS Newswire

Jun 29, 2025
pulisher
Jun 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Jun 27, 2025

Sage Therapeutics Inc Stock (SAGE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):